DL-TBOA

Modify Date: 2025-08-25 10:46:40

DL-TBOA Structure
DL-TBOA structure
Common Name DL-TBOA
CAS Number 205309-81-5 Molecular Weight 478.449
Density N/A Boiling Point N/A
Molecular Formula C11H13NO5 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of DL-TBOA


DL-TBOA is a potent non-transportable inhibitor of excitatory amino acid transporters with IC50s of 70 μM, 6 μM and 6 μM for excitatory amino acid transporter-1 (EAAT1), EAAT2 and EAAT3, respectively. DL-TBOA inhibits the uptake of [14C]glutamate in COS-1 cells expressing the human EAAT1 and EAAT2 with Ki valuesof 42 μM and 5.7 μM, respectively. DL-TBOA blocks EAAT4 and EAAT5 in a competitive manner with Ki values of 4.4 μM and 3.2 μM, respectively[1][2][3].

 Names

Name (3R)-3-(Benzyloxy)-D-aspartic acid-(3S)-3-(benzyloxy)-L-aspartic acid (1:1)
Synonym More Synonyms

 DL-TBOA Biological Activity

Description DL-TBOA is a potent non-transportable inhibitor of excitatory amino acid transporters with IC50s of 70 μM, 6 μM and 6 μM for excitatory amino acid transporter-1 (EAAT1), EAAT2 and EAAT3, respectively. DL-TBOA inhibits the uptake of [14C]glutamate in COS-1 cells expressing the human EAAT1 and EAAT2 with Ki valuesof 42 μM and 5.7 μM, respectively. DL-TBOA blocks EAAT4 and EAAT5 in a competitive manner with Ki values of 4.4 μM and 3.2 μM, respectively[1][2][3].
Related Catalog
Target

IC50: 70 μM (EAAT1), 6 μM (EAAT2) and 6 μM (EAAT3); Ki: 42 μM (human EAAT1), 5.7 μM (human EAAT2), 4.4 μM (EAAT4) and 3.2 μM (EAAT5)[1][2][3]

In Vitro DL-TBOA (70-350 μM; 48 hours; HCT116 and LoVo cell lines) treatment concentration-dependently enhances SN38-induced loss of viability. DL-TBOA reversed Oxaliplatin-induced loss of viability[4]. DL-TBOA (350 μM; 24 hours; HCT116 and LoVo cell lines) treatment decreases p53 induction by SN38 and oxaliplatin[4]. Cell Viability Assay[4] Cell Line: HCT116 and LoVo cell lines Concentration: 70 μM or 350 μM Incubation Time: 48 hours Result: Enhanced SN38-induced, and counteracted Oxaliplatin-induced, cell death. Cell Viability Assay[4] Cell Line: HCT116 and LoVo cell lines Concentration: 350 μM Incubation Time: 24 hours Result: p53 induction by SN38 and oxaliplatin was decreased.
References

[1]. Shimamoto K, et al. DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol Pharmacol. 1998 Feb;53(2):195-201.

[2]. Jabaudon D, et al. Inhibition of uptake unmasks rapid extracellular turnover of glutamate of nonvesicular origin. Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8733-8.

[3]. Shigeri Y, et al. Effects of threo-beta-hydroxyaspartate derivatives on excitatory amino acid transporters (EAAT4 and EAAT5). J Neurochem. 2001 Oct;79(2):297-302.

[4]. Pedraz-Cuesta E, et al. The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells. BMC Cancer. 2015 May 16;15:411.

 Chemical & Physical Properties

Molecular Formula C11H13NO5
Molecular Weight 478.449
Exact Mass 478.158752

 Synonyms

D-Aspartic acid, 3-(phenylmethoxy)-, (3R)-, compd. with L-aspartic acid, 3-(phenylmethoxy)-, (3S)- (1:1)
(3R)-3-(Benzyloxy)-D-aspartic acid - (3S)-3-(benzyloxy)-L-aspartic acid (1:1)
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.
Top Suppliers:I want be here



Get all suppliers and price by the below link:

DL-TBOA suppliers


Price: ¥2400/1 mg

Reference only. check more DL-TBOA price

Related Compounds: More...
DL-TBOA ammonium
2093503-71-8
(2S,3S)-2-Amino-3-benzylsuccinic ammonium salt,DL-TBOA
871123-98-7
DL-Tagatose
73952-11-1
DL-threo-Chloramphenicol D5
1420043-66-8
DL-Arginine
7200-25-1
DL-cysteine hydrochloride monohydrate
116797-51-4
DL-AP7
78966-69-5
DL-Homocysteine
6027-13-0
DL-Methylephedrine hydrochloride
18760-80-0
N-(4-chlorophenyl)-2-{[3-(2-methylphenyl)-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl}acetamide
1291862-84-4
N-(2,5-dimethylphenyl)-2-{[3-(2-methylphenyl)-4-oxo-3H,4H-thieno[3,2-d]pyrimidin-2-yl]sulfanyl}acetamide
1291832-31-9
N-(3-chloro-2-methylphenyl)-2-{[3-(2-methylphenyl)-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl}acetamide
1291839-19-4
N-(3-bromophenyl)-2-{[3-(2-methylphenyl)-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl}acetamide
1291867-44-1
2-{[3-(2-methylphenyl)-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl}-N-(propan-2-yl)acetamide
1291844-39-7
2-{[2-(6-methyl-2,3-dihydro-4H-1,4-benzoxazin-4-yl)-2-oxoethyl]sulfanyl}-3-(2-methylphenyl)thieno[3,2-d]pyrimidin-4(3H)-one
1291847-84-1
N-(3-methoxybenzyl)-2-{[3-(2-methylphenyl)-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl}acetamide
1291873-75-0
N-(4-chlorobenzyl)-2-{[3-(2-methylphenyl)-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl}acetamide
1291862-92-4
N-(1,3-benzodioxol-5-yl)-2-{[3-(2-methylphenyl)-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl}acetamide
1291860-06-4
Methyl 4-[({[3-(2-methylphenyl)-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl}acetyl)amino]benzoate
1291856-09-1